Transfusion and Apheresis Science最新文献

{"title":"Considerations on risk mitigating strategies for bacterial contamination of platelet concentrates – The Dutch perspective","authors":"Pieter F. van der Meer ,&nbsp;Vĕra M.J. Novotny ,&nbsp;Thomas L.R. Klei","doi":"10.1016/j.transci.2025.104087","DOIUrl":"10.1016/j.transci.2025.104087","url":null,"abstract":"<div><div>Due to their storage at room temperature, platelet concentrates are at risk for bacterial outgrowth if the unit is contaminated. Nowadays, various mitigation strategies are available, including bacterial screening and pathogen inactivation. Since pathogen inactivation technologies impact the clinical efficacy of the platelets, including but not limited to lower increments after transfusion and more significant bleeding, a balance needs to be struck between the safety and efficacy of platelet transfusions. In this Brief Review, we discuss the current situation in the Netherlands.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104087"},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143376682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative assessment of hemostasis in septic patients and healthy controls using standard coagulation tests and whole-blood thromboelastometry","authors":"Ecaterina Scarlatescu ,&nbsp;Paul Y. Kim ,&nbsp;Sergey P. Marchenko ,&nbsp;Dana R. Tomescu","doi":"10.1016/j.transci.2025.104082","DOIUrl":"10.1016/j.transci.2025.104082","url":null,"abstract":"<div><h3>Background</h3><div>Sepsis is associated with dysregulation of procoagulant, anticoagulant, and fibrinolytic pathways.</div></div><div><h3>Aims</h3><div>To compare the measurements of coagulation activation, clot formation, stabilization, and lysis between rotational thromboelastometry (ROTEM) and standard coagulation tests (SCTs) on patients with early sepsis (SP) and healthy controls (HC).</div></div><div><h3>Methods</h3><div>This observational study included 30 SP and 30 HC. At study inclusion, SCTs and ROTEM analyses were conducted. A modified ROTEM with exogenous tPA was used to investigate fibrinolysis resistance.</div></div><div><h3>Results</h3><div>SP had longer prothrombin time, higher fibrinogen levels and lower platelet count compared to HC. On ROTEM, clotting initiation was longer in SP than in HC but median clotting time maintained within reference ranges. SP had higher maximum velocity of clot formation, clot firmness, elasticity, and platelet component than HC. Clot lysis indices (CLI) were higher in EXTEM and APTEM (without and with added tPA) in SP compared to HC. The difference in CLI between APTEM and EXTEM was lower for both native and tPA-spiked samples in SP compared with HC.</div></div><div><h3>Conclusions</h3><div>While SCTs suggest SP are hypocoagulable, VET revealed normal coagulation initiation in more than 80 % of SP. Compared to HC, SP had increased clot propagation, firmness and elasticity, and decreased platelet-mediated clot retraction and lysis. In sepsis, VET provide more comprehensive information about hemostatic changes than SCTs.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104082"},"PeriodicalIF":1.4,"publicationDate":"2025-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143148931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What should be the optimal dose of post-transplantation cyclophosphamide for GVHD prophylaxis in allogeneic stem cell transplantation?","authors":"Turgay Ulas ,&nbsp;Sinem Namdaroglu ,&nbsp;Ipek Yonal Hindilerden ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Kerim Erer ,&nbsp;Tugce Nur Yigenoglu ,&nbsp;Tarik Onur Tiryaki ,&nbsp;Emine Hidayet ,&nbsp;Serdal Korkmaz ,&nbsp;Bahar Uncu Ulu ,&nbsp;Seda Yilmaz ,&nbsp;Emin Kaya ,&nbsp;Mehmet Sezgin Pepeler ,&nbsp;Abdulkadir Basturk ,&nbsp;Mehmet Sinan Dal ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104058","DOIUrl":"10.1016/j.transci.2024.104058","url":null,"abstract":"<div><h3>Objectives</h3><div>In this study, we aimed to compare the engraftment days, graft versus host disease (GVHD) development, relapse and overall survival (OS) rates in patients using variable intensity conditioning regimens with two different post-transplant cyclophosphamide (PTCy) doses for hematological malignancies.</div></div><div><h3>Material and methods</h3><div>We retrospectively analyzed 162 patients who have had PTCy at a dose of 25 mg/kg × 2 and 50 mg/kg × 2 between 2018 and 2024. Patients were divided in 2 groups; PTCy dose with 25 mg/kg × 2 (Group 1, n = 45) and PTCy dose with 50 mg/kg × 2 (Group 2, n = 117). The engraftment days, GVHD, relapse and OS rates were compared across groups.</div></div><div><h3>Results</h3><div>All patients had myeloablative conditioning regimens and peripheral stem cell collected transplantation. 61.1 % of patients (n = 99) were alive at the end of the study (60 % (n = 27) in Group1 and 61.5 % (n = 72) in Group 2). In Group 1 the median follow-up was 6.9 months and in Group 2 this was 7 months; the median OS was 15.5 months in Group 1 and 49.5 months in Group 2 but this is not statistically significant (Log rank = 0.796). In Group 1, the engraftment times for platelets was 13 days, for neutrophils 17 days; in Group 2, for platelet this was 18 days; and for neutrophils 17 days; this was statistically significant for platelets but not for neutrophil engraftment (p: &lt; 0.001 and p:0.839, respectively). Eighteen patients (40 %) in Group 1 and twenty-seven (23 %) patients in group 2 had acute GVHD (aGVHD). In Group 1 aGVHD rates were higher than Group 2 (p = 0.031). Seven patients (15.5 %) in Group 1 and 6 (5.12 %) patients in group 2 had chronic GVHD (cGVHD). In Group 1 cGVHD rates were also higher than Group 2 (p = 0.048). Twenty-five patients (55.6 %) in Group 1 and 19 patients (16.2 %) in Group 2 had relapsed disease (p &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Our study showed that there were no differences in survival across the groups. The platelet engraftment time was shorter for the PTCy 25 mg/kg × 2 doses compared to the post-transplantation 50 mg/kg × 2 doses. Both aGVHD and cGVHD rates were higher in 25 mg/kg × 2 dose treated patients. Relapses occurred more commonly with 25 mg/kg × 2 PTCy dose.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104058"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in patients with thrombotic microangiopathy associated with a trigger following plasma exchange: A systematic literature review","authors":"Shinya Kaname ,&nbsp;Moh-Lim Ong ,&nbsp;Jonathan Mathias ,&nbsp;Francesca Gatta ,&nbsp;Lisa Law ,&nbsp;Yan Wang","doi":"10.1016/j.transci.2024.104048","DOIUrl":"10.1016/j.transci.2024.104048","url":null,"abstract":"<div><div>Plasma exchange (PE) outcomes in patients with trigger-associated thrombotic microangiopathy (TMA) have not been comprehensively reviewed. Embase and MEDLINE® were searched on 03/14/2022 for English language articles published after 2007, alongside a congress materials search (2019–2022; PROSPERO: CRD42022325170). Studies with patients with trigger-associated TMA (excluding thrombotic thrombocytopenic purpura, ‘typical’ hemolytic uremic syndrome caused by Shiga toxin-producing <em>Escherichia coli</em>, post-partum TMA, and TMAs with known genetic cause) who received PE or plasma infusion (PI) and reported treatment response (including measures), safety, patient-/caregiver-reported outcomes, or economic burden data were examined. The NICE quality appraisal checklist assessed bias risk. After screening 695 articles, 49 PE or PI studies were identified, of which 42 reported PE exclusively; most were retrospective observational studies (n = 37). The most common TMA trigger was transplantation (n = 12). The median number of PE sessions was 3.5–25.0. Outcomes following PE varied by trigger type. Treatment response rates and definitions varied (0–100 %; 24 studies); in studies of &gt; 25 patients, response rates were 5–63 %. TMA relapse rates were 0–67 % (7 studies). Mortality was 10–91 % (23 studies). Progression to chronic kidney disease (CKD; 5 studies) and end-stage renal disease (ESRD; 6 studies) occurred in 0–93 % and 17–100 % of patients, respectively. Two serious adverse events were identified (transfusion-related injury, acute lung injury; 10 studies; 231 patients). Patients with trigger-associated TMA may experience a substantial burden in terms of mortality, relapse, and progression to CKD and ESRD following PE, leading to increased healthcare resource utilization. Additional interventions may be required.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104048"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142899623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of anticoagulant combinations used in granulocyte apheresis","authors":"Bera Omer Ugurlu ,&nbsp;Tulay Karaagac Akyol ,&nbsp;Olgu Erkin Çınar ,&nbsp;Osman Ozcebe","doi":"10.1016/j.transci.2024.104044","DOIUrl":"10.1016/j.transci.2024.104044","url":null,"abstract":"<div><div>Our study retrospectively examines the number of granulocytes in the products of donors who donated granulocytes between January 2016 and September 2020 at the Hacettepe University Faculty of Medicine Blood Bank. The effects of acid-citrate-dextrose (ACD), trisodium citrate + hydroxyethyl starch (TCC + HES) and ACD + HES combinations used in the apheresis procedure on the granulocyte count of apheresis products were examined. As a result of study, it was seen that the type of anticoagulant combination used during apheresis significantly affected the number of granulocytes collected.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104044"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142814638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What is the role of alpha-1 antitrypsin in the management of acute graft versus host disease?","authors":"Tugce Nur Yigenoglu ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Simten Dagdas ,&nbsp;Bahar Uncu Ulu ,&nbsp;Irfan Kuku ,&nbsp;Ali Durdu ,&nbsp;Mehmet Sezgin Pepeler ,&nbsp;Sinem Kul ,&nbsp;Mehmet Sinan Dal ,&nbsp;Emin Kaya ,&nbsp;Serdal Korkmaz ,&nbsp;Turgay Ulaş ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104057","DOIUrl":"10.1016/j.transci.2024.104057","url":null,"abstract":"<div><h3>Objective</h3><div>Acute graft versus host disease (GVHD) occurs in 20–80 % of patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Of these patients, 40 % will be resistant to steroids, which is the standard first-line approach. There is no standard second line treatment approach for patients with steroid refractory acute GVHD (SR-aGVHD). Alpha-1 antitrypsin is a protease inhibitor and has anti-inflammatory and immune regulatory properties. Here we report the outcomes and safety data of 17 patients treated with alpha-1 antitrypsin for SR-aGVHD.</div></div><div><h3>Material and methods</h3><div>Patients who received at least 2 lines of alpha-1 antitrypsin treatment for SR-aGVHD at five transplant centers in Türkiye were included in this retrospective study.</div></div><div><h3>Results</h3><div>The median number of alpha-1 antitrypsin treatment line patients received was 4 (range, 2–5). The median time between alpha-1 antitrypsin administration and response was 65 days (range, 10–138 days). Overall response rate was 70.6 %. When the first- and second-month response rates were compared according to GVHD organ involvement, we found that the response rates were similar in skin, liver and gastrointestinal system involvement (p = 0.281 and p = 0.305, respectively). No grade 3–4 anemia, thrombocytopenia or neutropenia was observed after alpha-1 antitrypsin treatment. Two patients had cytomegalovirus infection and 1 patient had pneumonia. At a median follow-up of 7 months, overall survival was 70.6 % and median overall survival was not reached.</div></div><div><h3>Conclusion</h3><div>In conclusion, alpha-1 antitrypsin is an effective and safe treatment option in patients with SR-aGVHD, with response rates of up to 70 % in patients with skin, liver and gastrointestinal system involvement. Larger studies are needed to establish a standard second and subsequent treatment approach in patients with SR-aGVHD.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104057"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive SWOT and TOWS analysis of transfusion medicine: Indian Perspective","authors":"Akshay Chopra,&nbsp;Shamee Shastry,&nbsp;Ganesh Mohan,&nbsp;Deepika Chenna,&nbsp;Vinu Rajendran","doi":"10.1016/j.transci.2024.104061","DOIUrl":"10.1016/j.transci.2024.104061","url":null,"abstract":"<div><h3>Background and objective</h3><div>SWOT and TOWS analysis is a strategic planning tool for identifying internal and external factors influencing a field. It helps to identify areas for improvement and growth by maximizing strengths and opportunities while minimizing weaknesses and threats. Transfusion medicine specialists can better understand the field's current status and plan potential growth using SWOT and TWOS strategic tools.</div></div><div><h3>Methods</h3><div>A cross-sectional questionnaire-based study using Google Forms, was conducted among Transfusion Medicine specialists in India. The authors formulated five open-ended questions for each of the S, W, O, and T categories to address and analyze the main aspects of Strengths, Weaknesses, Opportunities, and Threats. Descriptive statistics analyzed demographic details and keywords, extracting factors for SWOT and TOWS analysis to develop strategies.</div></div><div><h3>Results</h3><div>71 specialists, across India: Central (8), East (7), North (18), South (31), and West (7) responded, achieving a 48 % response rate. Strengths focused on Immunohematology and blood safety. Conversely, weaknesses highlighted were limited clinical exposure and insufficient recognition within the medical fraternity. Fostering interdisciplinary collaboration and integrating emerging advancements were key opportunities identified. The prevailing concerns encompassed two primary threats: the potential overlap with related branches like pathology, and the emergence of artificial blood products. The SO, ST, WO, and WT strategies focused on apheresis, recruitment policy, clinical exposure, and newer developments, respectively.</div></div><div><h3>Conclusion</h3><div>This study highlights the application of SWOT and TWOS analysis as a valuable strategic tool for Transfusion Medicine specialists to address these factors proactively and to enhance the field's trajectory.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104061"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platelet proteomics: Clinical implications – Decoding the black box!","authors":"Hadi Goubran ,&nbsp;Shahid Ahmed ,&nbsp;Gaafar Ragab ,&nbsp;Jerard Seghatchian ,&nbsp;Thierry Burnouf","doi":"10.1016/j.transci.2024.104060","DOIUrl":"10.1016/j.transci.2024.104060","url":null,"abstract":"<div><div>Platelets are anucleate blood cells traditionally associated with hemostasis but now increasingly recognized for their multifaceted roles in immunity, inflammation, and tissue repair. Advances in platelet proteomics, employing high-throughput techniques such as mass spectrometry, have significantly enhanced our understanding of platelet biology and its clinical implications in transfusion medicine. Platelet proteomics offers a retrospective view of physiological and pathological changes over the platelet's 7–10-day lifespan, making it a unique tool for studying cumulative biological events. Recent applications include the identification of biomarkers for cardiovascular, infectious, autoimmune diseases and cancer. In neurodegeneration and aging, platelets have been explored for their shared molecular pathways with neurons, with findings implicating Tau, amyloid-beta, and alpha-synuclein as potential biomarkers. Proteomics is also emerging as an important factor in the development of evidence-based, tailor-made platelet-derived therapies. While promising, platelet proteomics requires further standardization and computational advances to support transitioning from research to routine clinical practice.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104060"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is there a relationship between vitamin D levels and graft versus host disease?","authors":"Tugce Nur Yigenoglu ,&nbsp;Bahar Uncu Ulu ,&nbsp;Sinem Namdaroglu ,&nbsp;Mehmet Ali Erkurt ,&nbsp;Rasim Sahin ,&nbsp;Nazik Okumus ,&nbsp;Seda Yilmaz ,&nbsp;Funda Ceran ,&nbsp;Mehmet Koca ,&nbsp;Ugur Hatipoglu ,&nbsp;Mehmet Sinan Dal ,&nbsp;Serdal Korkmaz ,&nbsp;Turgay Ulas ,&nbsp;Fevzi Altuntas","doi":"10.1016/j.transci.2024.104054","DOIUrl":"10.1016/j.transci.2024.104054","url":null,"abstract":"<div><h3>Objective</h3><div>Vitamin D deficiency is common in adult patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT). Since vitamin D is an important regulatory factor for the immune system, vitamin D deficiency may have effects on antitumor activity, relapse rates, graft versus host disease (GVHD) occurrence and infection rates in allo-HSCT. We aimed to investigate the effects of vitamin D levels on the outcome of allo-HSCT.</div></div><div><h3>Material and methods</h3><div>This study included 211 patients who underwent allo-HSCT at seven transplant centers in Türkiye. The impact of pretransplant vitamin D level on overall survival (OS), relapse rate, GVHD occurrence and engraftment times was analyzed retrospectively</div></div><div><h3>Results</h3><div>Pretransplant vitamin D levels were not related to the neutrophil engraftment day (p: 0.887), relapse rate (p: 0.433) and GVHD occurrence (p: 0.391). At a median follow-up of 14 months, OS was 84.8 % and median OS was not reached. Univariate Cox Regression analysis showed that higher levels of vitamin D (&gt;12 ng/mL) affected the survival rates (p = 0.029) (HR: 0.392: 95 % CI: 10.170–0.907).</div></div><div><h3>Conclusion</h3><div>In our study, pretransplant vitamin D levels were not related to GVHD occurrence, relapse rate and engraftment times. However, we found that higher levels of pretransplant vitamin D levels (threshold is 12 ng/mL) were associated with increased survival. Further studies with a larger population are necessary to reveal the role of vitamin D in patients undergoing allo-HSCT.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104054"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of multiple apheresis platelet donations for the iron nutrition condition and platelet parameters of blood donors in China: A meta-analysis study","authors":"Quan Sun ,&nbsp;Liying Wu ,&nbsp;Yao Shen ,&nbsp;Le Wang ,&nbsp;Xiujuan Shen","doi":"10.1016/j.transci.2024.104043","DOIUrl":"10.1016/j.transci.2024.104043","url":null,"abstract":"<div><h3>Background</h3><div>Apheresis platelets is a common platelets collection method with high purity and relatively few adverse reactions. This study aimed to explore the effects of multiple apheresis platelet donations on the condition of iron nutrition and platelet parameters of donors in China.</div></div><div><h3>Methods</h3><div>Eligible studies were selected from PubMed, EMBASE, Wanfang, CQVIP, and the Chinese National Knowledge Infrastructure (CNKI) databases. Pooled serum ferritin (SF), serum iron (SI), transferrin (TRF), soluble transferrin receptor (sTfR), platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and platelet crit (PCT) were analyzed by weighted mean difference (WMD). Heterogeneity was detected by the Cochran Q test and <em>I</em>² statistical test.</div></div><div><h3>Results</h3><div>Pooled SF (WMD =-20.837, 95 % CI = −26.403 - −15.271) and SI (WMD = −3.828, 95 % CI = −6.516 - −1.139) were significantly decreased; while TRF (WMD = 0.821, 95 % CI = 0.271–1.371) and sTfR (WMD = 0.846, 95 % CI = 0.442–1.250) were increased by multiple apheresis platelet donations. PLT (WMD = 14.894, 95 % CI = 2.574–27.215) and PCT (WMD = 0.035, 95 % CI = 0.005–0.064) were increased, but MPV (WMD = −0.359, 95 % CI = −0.571 - −0.147) was reduced by multiple donations. Subgroup analysis indicated study design is a source of heterogeneity.</div></div><div><h3>Conclusion</h3><div>Multiple apheresis platelets could lead to iron deficiency and suppress platelet function in comparison with first-time apheresis platelets.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104043"},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142848196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}